Alberto Bardelli Selected Research

Proteasome Endopeptidase Complex (Proteasome)

1/2023	Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient.
12/2013	BRAF V600E is a determinant of sensitivity to proteasome inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alberto Bardelli Research Topics

Disease

145	Neoplasms (Cancer) 03/2024 - 11/2003
112	Colorectal Neoplasms (Colorectal Cancer) 04/2024 - 08/2002
15	Neoplasm Metastasis (Metastasis) 01/2022 - 11/2003
14	Disease Progression 01/2021 - 07/2009
8	Breast Neoplasms (Breast Cancer) 01/2021 - 11/2004
7	Colonic Neoplasms (Colon Cancer) 01/2019 - 11/2004
6	Melanoma (Melanoma, Malignant) 01/2023 - 08/2009
5	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 02/2014
5	Lung Neoplasms (Lung Cancer) 01/2021 - 09/2014
4	Carcinogenesis 01/2024 - 05/2004
4	Circulating Neoplastic Cells 08/2020 - 02/2014
4	Residual Neoplasm 09/2017 - 01/2008
4	Glioblastoma (Glioblastoma Multiforme) 09/2014 - 01/2009
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 01/2019
3	Microsatellite Instability 01/2021 - 04/2010
3	Pancreatic Neoplasms (Pancreatic Cancer) 08/2017 - 10/2011
3	Adenocarcinoma 12/2016 - 08/2009
3	Carcinoma (Carcinomatosis) 11/2010 - 07/2009
2	Mucinous Adenocarcinoma (Mucinous Carcinoma) 01/2023 - 01/2017
2	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2019 - 01/2017
2	Cholangiocarcinoma 01/2019 - 01/2017
2	Hypoxia (Hypoxemia) 02/2012 - 07/2009
2	Stomach Neoplasms (Stomach Cancer) 04/2010 - 05/2004

Drug/Important Bio-Agent (IBA)

29	Cetuximab (Erbitux)FDA Link 03/2020 - 05/2005
28	ErbB Receptors (EGF Receptor)IBA 04/2024 - 05/2005
23	Monoclonal AntibodiesIBA 01/2023 - 05/2005
23	Panitumumab (Vectibix)FDA Link 01/2022 - 05/2005
22	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 08/2002
20	Biomarkers (Surrogate Marker)IBA 05/2023 - 10/2009
16	Proteins (Proteins, Gene)FDA Link 02/2024 - 11/2004
15	Phosphotransferases (Kinase)IBA 01/2021 - 05/2004
13	Circulating Tumor DNAIBA 04/2024 - 02/2014
12	Cell-Free Nucleic AcidsIBA 05/2023 - 08/2013
11	AntibodiesIBA 06/2023 - 08/2010
10	Calcibiotic Root Canal SealerIBA 01/2023 - 11/2003
10	Immune Checkpoint InhibitorsIBA 01/2023 - 12/2018
8	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018 - 05/2012
6	Phosphoric Monoester Hydrolases (Phosphatases)IBA 09/2015 - 11/2003
5	RNA (Ribonucleic Acid)IBA 03/2024 - 01/2021
5	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2022 - 12/2016
4	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 02/2024 - 08/2005
4	Small Interfering RNA (siRNA)IBA 02/2022 - 04/2014
4	olaparibIBA 01/2022 - 10/2018
4	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 01/2017
4	Tyrosine (L-Tyrosine)FDA Link 09/2010 - 05/2003
3	AntigensIBA 03/2024 - 11/2018
3	pevonedistatIBA 01/2023 - 01/2017
3	TrabectedinIBA 01/2022 - 10/2018
3	Messenger RNA (mRNA)IBA 01/2021 - 11/2003
3	Lapatinib (GW572016)FDA Link 12/2020 - 06/2016
3	Trastuzumab (Herceptin)FDA Link 12/2020 - 06/2016
3	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 03/2004
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 04/2014
3	Adenosine Triphosphate (ATP)IBA 01/2019 - 07/2007
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2017 - 12/2010
3	Codon (Codons)IBA 06/2016 - 10/2010
2	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 02/2024 - 01/2021
2	carfilzomibIBA 02/2024 - 12/2013
2	Peptides (Polypeptides)IBA 01/2024 - 01/2008
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2024 - 12/2016
2	Proteasome InhibitorsIBA 01/2023 - 12/2013
2	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2023 - 12/2013
2	Heme (Haem)IBA 02/2022 - 01/2021
2	Alkylating AgentsIBA 12/2021 - 01/2017
2	Apoptosis Regulatory ProteinsIBA 01/2021 - 01/2017
2	Oxygen (Dioxygen)IBA 01/2021 - 07/2009
2	ChromatinIBA 01/2021 - 04/2014
2	pertuzumabIBA 12/2020 - 01/2020
2	MicroRNAs (MicroRNA)IBA 08/2020 - 02/2014
2	Ascorbic Acid (Vitamin C)FDA LinkGeneric 03/2020 - 01/2020
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020 - 01/2019
2	infigratinibIBA 01/2019 - 01/2017
2	regorafenibIBA 01/2019 - 12/2016
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2019 - 01/2017
2	futuximabIBA 04/2018 - 01/2016
2	Growth Factor ReceptorsIBA 01/2018 - 05/2005
2	Transcription Factors (Transcription Factor)IBA 08/2017 - 11/2004
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2017 - 05/2013
2	Gemcitabine FDA Link 12/2016 - 11/2010
2	Angiopoietin-2IBA 12/2016 - 02/2015
2	VemurafenibIBA 01/2016 - 01/2012
2	entrectinibIBA 01/2016 - 01/2016
2	PLX 4720IBA 12/2013 - 02/2012
2	Protein Kinases (Protein Kinase)IBA 03/2013 - 09/2010
2	Oncogene Proteins (Oncogene Protein)IBA 01/2012 - 11/2011
2	Mitogen-Activated Protein KinasesIBA 10/2011 - 03/2007
2	Estrogen ReceptorsIBA 06/2010 - 01/2008
2	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 04/2010 - 01/2009
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 02/2008 - 01/2008
2	Antineoplastic Agents (Antineoplastics)IBA 10/2005 - 12/2004
1	HMGB1 Protein (HMG1)IBA 02/2024
1	Protein-Arginine N-Methyltransferases (Methyltransferase, Protein Arginine)IBA 02/2024
1	CalreticulinIBA 02/2024

Therapy/Procedure

78	Therapeutics 03/2024 - 10/2004
12	Drug Therapy (Chemotherapy) 01/2022 - 03/2004
10	Immunotherapy 01/2024 - 01/2018
4	Retreatment 11/2023 - 02/2019
3	Precision Medicine 01/2020 - 11/2011
2	Aftercare (After-Treatment) 01/2019 - 05/2005
1	Intravenous Administration 02/2024